Helix BioPharma Corp. announces the receipt of subscription agreements

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and  warrants for aggregate net proceeds in excess of  CDN$4.6 million after expected expenses.